BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
BIODESIX INC income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -20.0%
- Net margin
- -27.0%
- Return on equity, FY2025
- -383.1%
Financial strength
- Current ratio
- 2.85
- Debt to equity
- 5.12
- Debt to assets
- 49.1%
- Cash to current liabilities
- 196.2%
Valuation
- P/E ratio
- –
- Price to sales
- 2.34
- Price to book
- 26.35
- Dividend yield
- –